Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol

Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol

Introduction Immunotherapy with checkpoint inhibitors (CPIs) has revolutionised cancer treatment but has no convincing effect in metastatic castration-resistant prostate cancer (mCRPC). It has been suggested that a combination of CPI and hypofractionated stereotactic body radiotherapy (SBRT) may wor...

Full description

Bibliographic Details
Main Authors: Henriette Lindberg, Inge Marie Svane, Estrid V Hogdall, Dorte Lisbeth Nielsen, Susann Theile, Nicklas Juel Spindler, Gitte Fredberg Persson, Gina Al-Farra, Helle Westergren Hendel, Torben Lorentzen, Rikke Løvendahl Eefsen
Format: Article
Language:English
Published: BMJ Publishing Group 2023-01-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/13/1/e063500.full

Internet

https://bmjopen.bmj.com/content/13/1/e063500.full

Similar Items